BRIEF-Nektar TherapeuticsReceived Letter From Nasdaq Notifying Co It Regained Compliance With Minimum Bid Price Requirement For Continued Listing On Nasdaq

Reuters04-18

April 17 (Reuters) - Nektar Therapeutics :

* NEKTAR THERAPEUTICS:RECEIVED LETTER FROM NASDAQ NOTIFYING CO IT REGAINED COMPLIANCE WITH MINIMUM BID PRICE REQUIREMENT FOR CONTINUED LISTING ON NASDAQ

Source text for Eikon: [ID: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2428372226?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-18 05:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2428372226","market":"us","top_or_hot":-1,"title":"BRIEF-Nektar TherapeuticsReceived Letter From Nasdaq Notifying Co It Regained Compliance With Minimum Bid Price Requirement For Continued Listing On Nasdaq","media":"Reuters","content":"<html><body><p>April 17 (Reuters) - Nektar <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>   :</p><p>   * NEKTAR THERAPEUTICS:RECEIVED LETTER FROM NASDAQ NOTIFYING CO IT REGAINED COMPLIANCE WITH MINIMUM BID PRICE REQUIREMENT FOR CONTINUED LISTING ON NASDAQ</p><p>Source text for Eikon: [ID: Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Nektar TherapeuticsReceived Letter From Nasdaq Notifying Co It Regained Compliance With Minimum Bid Price Requirement For Continued Listing On Nasdaq</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Nektar TherapeuticsReceived Letter From Nasdaq Notifying Co It Regained Compliance With Minimum Bid Price Requirement For Continued Listing On Nasdaq\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-18 05:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>April 17 (Reuters) - Nektar Therapeutics   :   * NEKTAR THERAPEUTICS:RECEIVED LETTER FROM NASDAQ NOTIFYING CO IT REGAINED COMPLIANCE WITH MINIMUM BID PRICE REQUIREMENT FOR CONTINUED LISTING ON ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2095319765.USD","symbol_name":"Natixis Thematics Subscription Economy R/A USD","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2428372226","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2428372226","pubTimestamp":1713390529,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"April 17 (Reuters) - Nektar Therapeutics   :   * NEKTAR THERAPEUTICS:RECEIVED LETTER FROM NASDAQ NOTIFYING CO IT REGAINED COMPLIANCE WITH MINIMUM BID PRICE REQUIREMENT FOR CONTINUED LISTING ON NASDAQSource text for Eikon: [ID: Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4112":"金融交易所和数据","QLD":"纳指两倍做多ETF","BK4588":"碎股","QQQ":"纳指100ETF","PSQ":"纳指反向ETF","SQQQ":"纳指三倍做空ETF","NKTR":"内克塔治疗","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4007":"制药","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","QID":"纳指两倍做空ETF",".IXIC":"NASDAQ Composite","TQQQ":"纳指三倍做多ETF","NDAQ":"纳斯达克OMX交易所","BK4585":"ETF&股票定投概念"},"translate_title":"简介-Nektar Therapeutics收到纳斯达克的信函，通知公司重新符合继续在纳斯达克上市的最低买入价要求","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NKTR":1,"NDAQ":1,".IXIC":1,"TQQQ":0.6,"SQQQ":0.6,"QQQ":0.6,"QLD":0.6,"QID":0.6,"PSQ":0.6,"NQmain":0.6,"MNQmain":0.6},"content_text":"April 17 (Reuters) - Nektar Therapeutics   :   * NEKTAR THERAPEUTICS:RECEIVED LETTER FROM NASDAQ NOTIFYING CO IT REGAINED COMPLIANCE WITH MINIMUM BID PRICE REQUIREMENT FOR CONTINUED LISTING ON NASDAQSource text for Eikon: [ID: Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2428372226"}